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11. Introduction
After the Chernobyl disaster the frequency of thyroid cancer has 
dramatically increased in children from Belarus [1-4]. The treatment for thyroid 
cancer is surgical removal of the tumour (thyroidectomy) followed by one or more 
treatments with radioiodine. In about a quarter of the Belarussian patients 
radioiodine therapy is performed at the Clinic for Nuclear Medicine of the University 
of Würzburg thanks to the financial support of the association of the German 
Electricity Companies (VDEW) and the ‘Medizinische Hilfe für Tschernobyl-Kinder’ 
Association.
The main risks of radioiodine treatment (RIT) are the induction of lung 
fibrosis and secondary cancers as a consequence of the genotoxic effects of the 
radioiodine radiation [5]. The frequency of somatic mutations in basic genes of 
erythrocytes and lymphocytes has been used as an indicator of the genotoxic 
effect of radiation [6-11]. The corresponding assays are 1) hypoxanthine-guanine 
phosphoribosyl transferase (HPRT), 2) glycophorin A (GPA), 3) T-cell receptor 
(TCR) assays. 
In the present investigation the TCR assay was applied to the thyroid cancer 
patients to quantify the genotoxic effect of the radioiodine therapy and to detect 
those patients who might have an increased cancer risk. The patients were 
represented by young patients from Belarus who were undergoing the radioiodine 
therapy in the Clinic of Nuclear Medicine. After the irradiation with radioiodine the 
increase in frequency of mutant TCR receptors could be seen after a six month 
latent period. In order to shorten this time, for some samples the cell culture of 
lymphocytes had been applied before TCR assay was done.
Another method of biological dosimetry used was the reticulocyte-
micronucleus assay. This method is long known and used in mice as a MN assay 
in polychromatic erythrocytes [12]. In humans the application of this assay was 
problematic because all the aberrant (in our case micronucleated) cells are quickly 
removed by the spleen. Therefore, in humans the assay was restricted to 
spleenectomized subjects. Recently the flow-cytometric in vivo micronucleus assay 
2has been adapted for use in humans [13]. This is done by immunomagnetic 
separation of immature transferrin-positive reticulocytes (Tf-Ret) present in the 
peripheral blood. The isolated Tf-Ret are then analysed for the presence of 
micronuclei. The results of this previous study indicated that micronuclei in human 
Tf-Ret could be a sensitive biomarker for chromosome damage. 
In order to investigate the utility and sensitivity of this method for the 
detection of radiation-induced chromosome damage, we have now performed a 
study of MN in Tf-Ret in 46 patients undergoing radioiodine therapy. These 
patients received defined activities of 131I, precise dosimetry during their 
hospitalisation, and sequential determinations of the individual frequencies of MN-
Tf-Ret. It was worth mentioning that this study was a first attempt of using MN-Tf-
Ret assay as a biological dosimeter.
32. Method
2.1. Thyroid cancer patients and radioiodine treatment (RIT)
In most assays blood from thyroid cancer patients was used. Blood was 
sampled with informed consent. The thyroid cancer was caused by radioiodine 
incorporation around the birth or in early childhood. 
The TCR assay was performed in 72 Belarusian young thyroid cancer 
patients, 30 males and 42 females aged between 14 and 25 years. There was no 
big difference in numbers of males and females, who took part in the study. Most 
patients were from the southern part of Belarus, which suffered heavily from the 
fallout of the Chernobyl accident. They had been thyroidectomised at the 
Republican Thyroid Cancer Centre in Minsk, Belarus before RIT in Würzburg. The 
data on patients at the time of thyroid cancer detection and TNM classification of 
the tumours are given in Tab. 1. All tumours were papillary thyroid carcinomas. 
Lymph nodes were involved in all patients except one. Many patients suffered from 
distant metastases mostly in their lungs. The unexposed control group consisted of 
19 patients not yet treated with radioiodine. Their mean age was 17 years.
In MN-Tf-Ret assay 23 young women and 21 young men from Belarus and 
2 elderly patients from Germany took part. The mean age of the Belarussian 
citizens was 19. Among them there were many patients with pathologically positive 
lymph nodes without (T2 N1 M0, n=23) or with metastases (T2 N1 M1, n=7). In 
some cases direct invasion of the tumour through the capsule of the thyroid gland 
was found without (T4 N1 M0, n=2) or with metastases (T4 N1 M1, n=14).
All of the patients of this study received the similar therapy. After the thyroid 
cancer was diagnosed the thyroid gland was surgically removed and treatment with 
radioiodine was started. Four weeks prior to every RIT thyroxine was withdrawn 
and all patients were definitely hypothyroid when radioiodine was administered as 
demonstrated by the high TSH level. As a consequence of hypothyroidism most 
patients felt tired immediately before RIT and their appetite was poor and 
constipation rather common. Two days after radioiodine administration thyroxine 
4replacement therapy was resumed by administration of about 2 g/kg L-thyroxine 
and symptoms of hypothyroidism disappeared. In patients with advanced disease, 
several RITs were needed to cure the cancer. 131I was given orally as capsules at 
an activity of approximately 50 MBq per kg BW in the first RIT for ablation of 
remnant thyroid tissue and 100 MBq/kg in the following RITs for elimination of 
metastases.  
Tab. 1 Thyroid cancer patients from Belarus investigated between 
October 2002 and June 2003 for TCR mutants
Parameter n %
Gender
     male 30 42
     female 42 58
Age at accident (April 26, 1986)
     ≤4 63 88
     >4 9 12
Residence at accident
     District Gomel 28 39
     District Brest 21 29
     Others 23 32
Age at Diagnoses 
     ≤14 33 46
     >14 39 54
TNM classification ( papillary thyroid carcinoma )
     T1 0 0
     T2 37 51
     T3 0 0
     T4 33 46
     Tx 2 3
     N0 0 0
     N1 70 97
     Nx 2 3
     M0 26 36
     M1 46 64
52.2. Assays
2.2.1. Standard T-Cell receptor (TCR) assay
The assay was performed mainly as described by Kyoizumi et al. [14]. 
Lymphocytes were isolated by Ficoll gradient centrifugation from a total of 6 ml 
heparinised blood. For flow cytometry about 5 million of lymphocytes were stained 
with fluorescein-labelled anti-Leu3a (CD4), phycoerythrin-labelled anti-Leu4 (CD3) 
antibodies (Becton Dickinson Immunocytometry Systems, San Jose, CA) and 
propidium iodide (PI) (20 g/ml). The frequency of CD3+ CD4+, CD3- CD4+, CD3+ 
CD4- and CD3- CD4- cells was determined using a Coulter EPICS XL-MCL flow 
cytometer (Coulter Co, Hialeah, Fl). Dead cells were excluded by the PI staining of 
their nuclei. TCR-Mf was the number of CD4+ CD3- cells divided by the total 
number of CD4+ cells. Every lymphocyte fraction was analysed twice and then the 
mean value was taken. Flow cytometric analysis and gating of lymphocytes are 
described in results.
2.2.2. Assay for latent TCR mutants
TCR assay for latent TCR mutants was done in parallel with standard TCR 
assay. So we used the same blood samples for both of them. All these patients 
were from Belarus. Their characteristics were as described above. We investigated 
26 of them, 18 females and 8 males, aged between 13 and 19 with mean value of 
18 years. For the assay it was important to separate the first time-treated patients 
from those treated 2 and more times.
Tab. 2 Number of treatments with radioiodine
Number of RIT Number of Patients
1 8
2 13
3 2
4 1
5 1
6 1
Totally: 26 patients
62.2.2.1. Culture of lymphocytes and detection of latent TCR mutants
In these patients blood was taken before and 96 hours after the RI 
(radioiodine) application. All the blood was taken in heparinised tubes. The blood 
taken before the RIT (18 ml) was divided into 3 samples. 1st blood sample was 
used for standard TCR assay as described above.
In 2nd and 3rd samples, as well as in the probe taken 96 hours after the 
start of treatment, the lymphocytes were isolated by ficoll gradient centrifugation 
and then washed twice in RPMI1640 by centrifugation (at +4oC, 1100 RPM, 30 
min, without brake). Lymphocytes from the 3rd sample were irradiated with 1Gy 
before the cell culture (Section 2.3.1). 
The amount of 4.6*106 cells was taken and placed in 23 ml of culture 
medium at 37oC, 5% CO2. The starting concentration was 0.2*106 cells per 1ml. 
The culture medium compounds are summarised in Tab. 3 [15]. Six days later the 
TCR assay was performed. When lymphocytes were cultured for more than 6 
days, half the culture medium was replaced every 2 days.
For the assay 5 to 10 ml culture medium were taken, cells were separated 
by pipetting, counted and washed twice with PBS. Finally, the pellet was 
suspended in 100 µl and cells were stained as usual for TCR assay. The overall 
cell concentration was calculated by multiplying the actual concentration in the 
solution by the dilution coefficient.
Tab. 3 Lymphocyte cell culture medium
Name of Compound Amount
RPMI1640 medium (Dutch modification) with 15% FBS 80  ml
AIM-V medium 20  ml
Penicillin-Streptomycin solution
  (conc.: Penicillin - 10000 E/ml, Streptomycin – 10000 ug/ml)
2  ml
Sodium-Pyruvat stock solution  (100 mM) 1 ml
Glutamax I stock solution (200 mM) 1 ml
Mercaptoethanol stock solution (50 mM) 100  µl
Phytohemagglutinin stock solution (3 µg/ml) 300  µl
Rec-IL-2 stock solution (400000 U/ml) 50  µl
72.2.2.2. Calibration of the assay in in vitro irradiated lymphocytes
Additionally, for TCR assay after in vitro culture and irradiation, we 
performed the calibration test to check the TCR-Mf response to different levels of in 
vitro irradiation. The procedure was the same as described above for sample 3, 
except that the blood was taken from a healthy volunteer with normal TCR-Mf base 
level and afterwards, it was divided into 6 samples, which were irradiated at doses
from 0 to 1 Gy with a 0.2 Gy step as described in Section 2.3.1.
2.2.3. MN-Tf-Ret assay
2.2.3.1. Isolation of transferrin receptor positive reticulocytes (Tf-Ret)
Coating of Dynabeads. 45 µl magnetic beads (CELLection Pan Mouse IgG 
Kit, Dynal, Oslo) were transferred to a conical tube. The tube was placed in a 
magnetic particle concentrator (MPC) for 1 minute. The liquid was removed and 
the beads were resuspended in 2 ml phosphate buffered saline pH 7.4 (PBS) with 
1% foetal calf serum (FCS). The tube was placed in the MPC for one minute and 
the liquid was taken away. The wash with PBS containing 1% FCS was repeated.. 
The beads were then resuspended in 100 µl PBS with 1% FCS and 7 µl mouse 
anti-human CD71 antibody was added. The tube was incubated for 30 minutes at 
room temperature with continuous rotation.  During this time the CD71 antibody 
was attached to the magnetic beads. After the incubation 2 ml PBS with 1% FCS 
was added and the tube was placed in the MPC for 1 minute. The liquid was 
removed and the bead-antibody complex was washed two more times with 2 ml 
PBS containing 1% FCS and finally suspended in 100 µl PBS with 1% FCS.
Isolation of Tf-Ret: Whole blood samples were taken by vein puncture. To 
remove the serum containing free transferrin receptors, 2 ml whole blood was 
placed in a tube together with 4 ml PBS (without FCS) and centrifuged at 400g for 
5 min at room temperature. The pellet was washed again in 4 ml PBS and 
centrifuged as before. The pellet was resuspended in 0.5 ml PBS. Then the blood 
cells were added to the tube with the bead-antibody complex. The tube was 
8incubated at 4C for 15 minutes with continuous rotation. This incubation allowed 
the cells with CD71 on their surfaces to attach to the bead-antibody complex.  
Thereafter the tube was placed in the MPC for 1 minute. The liquid was removed. 
The magnetically labelled cells were washed four times with 3 ml PBS containing 
1% FCS. Before the last wash the suspension was transferred to a new conical 
tube. The magnetically labelled cells were resuspended in 200 µl PBS with 1% 
FCS and 7 µl DNase from the CELLection Pan Mouse IgG Kit was added. The 
tube was incubated for 15 minutes at room temperature with continuous rotation.
During this step DNase released the cells from the beads due to enzymatic 
cleavage of the DNA-linker. The tube was then placed in the MPC for 1 minute. 
The fluid was collected into a new conical tube. The beads were washed with 200 
µl PBS containing 1% FCS four times and the fluid was collected into the tube with 
the released cells (final volume of 1 ml). Before the last wash the suspension was 
transferred to a new conical tube and the tube with the released cells was placed in 
MPC once more to remove residual beads. The cell suspension was collected to a 
new tube again.
2.2.3.2. Fixation of cells
The tube with the reticulocytes was centrifuged at 400g for 5 min at room 
temperature. The supernatant was discarded and the pellet was resuspended in 0.4 ml 
PBS with 10 µg/ml SDS. After one minute 2.5 ml 2% formaldehyde with 10 µg/ml SDS 
was added during mixing. The tube was stored in a dark place at room temperature for 
at least three days.
2.2.3.3. Flow cytometric analysis
Staining of cells: the tube with the cells was centrifuged at 400g for 5 
minutes at room temperature.  The pellet was resuspended in 0.5 ml staining 
solution prepared by mixing 10 ml PBS with 7.5 µl Hoechst 33342 stock solution 
(500mM) and 2 µl Thiazole orange (1 mg/ml). The tube was incubated at 37C for 
60 minutes. The tube was mixed every 20 minutes.
9Flow cytometry: The stained samples (whole blood and enriched 
reticulocytes) were analysed on a LSR flow cytometer (Becton-Dickinson, CA, 
USA) equipped with an argon ion laser operating at 488nm and a second HeCd ion 
laser operating at the 352 nm. The analysis rate was 300-1000 cells per second 
with a threshold in forward scatter (FSC) set to include all intact cells. Using 
CellQuest Pro software (Becton Dickinson, CA, USA) peak values for FSC, SSC, 
Thiazole orange fluorescence and Hoechst 33342 fluorescence signals were 
collected. The FSC signals were acquired using a linear scale and the SSC, 
Thiazole orange and Hoechst 33342 signals were acquired using a log scale. 
Between 100.000 and 200.000 events were collected from each sample.
2.3. Irradiation and dosimetry
2.3.1. Irradiation of lymphocytes
Lymphocytes were placed in 1 ml of ice-cold culture medium RPMI1640 in 
cryotubes and irradiated at dose 1 Gy, dose rate 1,62 Gy/min, with 0.66 MeV 
Photons from a calibrated 137Cs-source.
2.3.2. Calculation of bone marrow radiation dose in radioiodine therapy
In the case of MN assay for every patient individual dosimetry was done as 
described below. For TCR assay dosimetry on individual basis wasn’t possible, 
therefore, the retrospective dosimetry was done. Obviously, the restrospective 
dosimetry is less accurate and some mistakes inevitably occur.
2.3.2.1. Retrospective dosimetry according to ICRP
Dose determination is related to red marrow as central organ of 
hematopoiesis. The red marrow dose of radioiodine treated patients was calculated 
by the Eq. 1, where D is the total dose (mGy) in the red marrow, RM - the marrow 
dose per unit of activity administered (mGy/MBq), and A - total activity given. The 
value for RM was taken from pamphlet 53 [16] of ICRP (International Commission 
on Radiological Protection) using the data of the appropriate phantom. In ICRP 
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pamphlet all the coefficients are calculated for a person with a 70 kg weight, or a 
phantom. In our equation we took into account the actual difference between the 
patients-weight and phantom-weight, and represented it as additional coefficient. 
The factor 1.45 (SD = 0.29) accounts for the fact that the excretion of iodide ions in 
thyroidectomised and hypothyroid patients is much slower than assumed by ICRP 
for healthy individuals. Its value was found in an investigation with 22 young thyroid 
cancer patients (12 men and 10 women) [17], whose red marrow dose was 
calculated according to ICRP as well as measured as recommended by Medical 
Internal Radiation Dose (MIRD) Committee [18, 19]. 
WeightPatient
WeightPhantom
ARMD 
 45.1
Eq. 1
2.3.2.2. Individual dosimetry according to MIRD
Dosimetry is restricted on red marrow (RM) since this is the critical organ in 
MN-Tf-Ret biodosimetry. The following parameters were measured to calculate the 
dose to RM: a) the administered 131I activity 
A0  and b) the cumulated total body 
activity 
ATB . The latter was determined by sequential measuring of the total body 
activity (TBact ) with a calibrated survey meter nominally at 2 h, 4 h, 6 h, 12 h, 24 h, 
36 h, 48 h, 72 h, and 96 h after 131I administration. The initial whole body 
quantitation at 2h post-administration was performed with no interim voiding, 
allowing patient specific standardization of the survey meter. The area under the 
total activity curve is equal to ATB  . In calculation of the cumulated total body 
activity it was assumed that the decay from the last data point corresponds to the 
decay within the last 2 days. In some patients TBact  could not be measured for 96 
hours, since they left the hospital as soon as TBact  fell to less than 250 MBq. This 
value was the lower limit of TBact  when patients had to stay in the hospital 
according to German regulations.
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D A S RM RM A S RM RB
RM RM RB
     ( ) ( )
Eq. 2
Red marrow dose estimates were calculated by the two component Eq. 2 
[20], where DRM  is the red marrow dose estimate, ARM  is the red marrow 
cumulated activity, S RM RM( )  is the red marrow-to-red marrow S value, ARB
is the remainder of the body (RB) cumulated activity obtained by subtracting 
the red marrow value, ARM , from the total body value, and  RBRMS   is the 
remainder of the body-to-red marrow S value. S values were taken from 
MIRDOSE3 [18]. MIRDOSE3 assumes homogenous activity distribution throughout 
RB. As in bone components (i.e. trabecular and cortical bone) activity would be 
much lower than in other organs, bone was considered as a source region with 
zero residence time to avoid false cross-fire of electrons from bone to RM [19].
A A m
m
m CFRM blood RM el
TB patient
TB el
   ,mod ,
,mod Eq. 3
The red marrow cumulated activity, ARM , in Eq. 2 was determined  by Eq. 3, 
where 
A blood  is the cumulated activity per 1 liter blood, mRM el,mod  is the red 
marrow mass of the respective dosimetric model, 
mTB patient,  is total body mass of 
the patient, mTB el,mod  is the total body mass of the respective model. CF  is a 
correction factor for the marrow-to-blood activity concentration ratio. CF was set at 
unity under the assumption that iodide distributes equally between the water pool 
of blood and red marrow. In RIT of thyroidectomised patients 131I activity is present 
in the form of iodide. 
A blood  was not measured in the present investigation. It was 
calculated by the equation 
A blood = f A VTB blood /  where f  is a constant factor 
which corresponds to the cumulated activity ratio A Ablood TB/ [21, 22]. The value 
of f  is 0.123  0.015 (mean  SD). It was found by an investigation in 22 young 
adults whose cumulated total body activity as well as the cumulated blood activity 
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had been measured during RIT for thyroid cancer [17]. Vblood  is the patient's blood
volume, which was calculated considering the patient's gender, weight and height 
[23]. Some details about the treatment and radiation dose to red marrow are given 
in Tab. 4
2.3.3. Radiation dose due to diagnostic
Some hours before 131I administration every patient was screened for lung 
metastases by a CT examination of the chest (spiral CT scanner Somatom Plus 
4A, Siemens AG, Forchheim, Germany). The radiation dose applied by the CT 
scan is about 15 mSv to the red marrow of the thorax [24]. Bones of the thorax 
(sternum, ribs, scapulae, clavicles, and upper fourth of the humeri) contains in 
adult about 20 % of total red marrow [25]. The dose of diagnostic radiology was not 
considered. It should be less than 5% of the dose from radioiodine administration.
2.4. Statistics
For non-linear regression analysis the software SigmaStat 1.0 (Jandel 
Scientific, Erkrath, Germany) was applied, which uses the Marquardt-Levenberg 
algorithm to find the parameters of the variables that give the best fit.
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3. Results and Discussion
3.1. Bone marrow radiation dose in RIT
Some details about the treatment and the radiation dose to red marrow are 
given in Tab.4. In the first RIT about 50 MBq and second RIT about 100 MBq per 
kg BW were administered. Patients were exposed to an exponential decreasing 
low dose rate irradiation of ß- and g-rays for 3 to 6 days. In the first day after 
radioiodine administration, the dose rate was in the order of 5-10 mSv/h. The mean 
total radiation dose to red marrow (DRM ) was 182 and 475 mSv in the first and
Tab. 4    Radioiodine therapy and radiation dose to red marrow
No. of 131I Act. Age BW Pause a TSH b TB  c D24e DRM d
RIT (MBq / kg) (a) (kg) (y) (mU / L) (h) (mSv) (mSv)
1st 50 17.7  1.7 61  12 -- 190  119 16.9  3.1 137  16 182  32
(17) f (13.0 -
19.7)
(40 - 80) (14 - 431) (11.9 -
21.8)
(95 - 153) (112 -
223)
2nd 100 18.1 1.3 64  10 0.8  0.1 253  194 21.7  4.7 313  41 475  112
(17) f (14.5 -
19.8)
(42 - 82) (0.5 - 1.0) (56 - 688) (14.6 -
32.7)
(236- 378) (309 -
727)
3rd - 12th 100 18.8  1.8 70  13 1.6  1.3 283  132 18.3  2.4 289  27 398  60
(15) f (17.0 -
24.5)
(47 - 91)) (0.8 - 5.7) (104 -
633)
(14.4 -
22.3)
(250 -
332)
(308 -
484)
a Time interval between the present and previous RIT.
b Concentration of thyroid stimulating hormone (TSH) in plasma, value in healthy 
persons 0.3 – 4 mU/L
c Residence time (RT) of radioiodine in total body (TB). It was calculated by the 
equation TB TBA A / 0  where ATB  is cumulated total body activity and A0  is 
the administered activity.
d Radiation dose to red marrow, for details see 2.3.2; values are corrected for the 
indicated activity.
e Radiation dose during the first 24 h after 131I administration. It was calculated by 
the relation D DRM TB24 1 24   ( exp( / )) . D24  is the greatest radiation 
dose per cell cycle in late erythroblasts, for details see 4.2
f Only patients below age 25 at RIT
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second RIT, respectively. Though in each group about the same activity per kg BW 
was administered the red marrow dose scattered in a wide range in consequence 
of the considerable variation of the total body residence time () of radioiodine. The 
red marrow doses in our patients were in the same range as previously reported, if 
the differences and uncertainties in dose calculation are considered [22, 26, 27]. 
Besides, the total red marrow dose DRM  also the dose during the first 24 h of RIT 
(D24) is given. In the present study, the dose ratio D DRM24 /  varied between 0.47 
and 0.86 (median 0.72). It will be shown in Section 3.4.2.4 that the knowledge of 
D24  is a prerequisite for the understanding of the time curve of f(MN-Tf-Ret) in 
patients after RIT.
3.2. Standard TCR assay
3.2.1. Results (standard TCR assay)
3.2.1.1. TCR mutant frequency ( TCR-Mf ) in patients after  RIT
Fig. 1 represents examples flow of cytometric analysis of TCR mutants in a 
healthy person and in a patient treated several times with radioiodine. The mutant 
window used in the present investigation is as described by Kyoizumi et al. [14]. In 
their analysis the mutant window was set to the region where the CD3 level (FL2) 
was <4% of that of normal CD4+ cells. The left and right limits of FL1 were set at 
values half of and two times greater than the mode intensity of FL1 for normal CD4 
T-cells. The mean TCR-Mf of patients before 131I treatment, the so-called 
spontaneous mutant frequency, was 2.0  0.6  10 4  (mean  SD, n=25). TCR-Mf 
of the radioiodine treated patient was significantly higher than that of the untreated 
one.
In Tab. 5 the results of all TCR assays in radioiodine treated young patients 
are summarized. As it could be seen from the table, even more than 10 years after 
the last treatment TCR-Mf has not yet returned to normal.
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Fig. 1 Flow cytometric analysis of TCR mutant lymphocytes.
A. Healthy donor with normal level of TCR-Mf 1.7310-4. 
B. Sample of a patient treated with radioiodine 8 times between 1994 to 1999 with 
cumulated activity of 47GBq, TCR-Mf  4.8910-4. The gating of TCR mutants is 
described in text.
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Tab. 5   Time table of 131I treatment and TCR-Mf in treated patients from Belarus
Years
Patient
0 1 2 3 4 5 6 7 8 9 10 11 12
W240 1.6 *
W241 2.8 *
W242 2.4 *
W243 1.8 *
W244 1.5 *
W245 1.6 *
W222 * 1.9
W226 1.7 *
W229 1.7 * 2.4 *
W230 1.8 * 4.3 *
W231 1.9 * 2.6 *
W232 2.2 * 4.4 *
W233 1.8 * 1.8 *
W234 2.6 * 3.9 *
W235 2.8 * 4.2 *
W236 1.8 * 4.1 *
W237 1.2 * 3.6 *
W238 1.3 * 4.4 *
W239 3.3 * 4.6 *
W223 1.3 * 1.4 *
W224 1.7 * 2.2 *
W227 2.0 * 4.2 *
W214 * 2.9 *
W215 * 2.8 * 3.0
W216 * 2.2
W219 * 2.1 * 4.0 *
W220 1.5 * 2.8 *
W221 3.3 * 2.5 * 5.4* 8.5 *
W225 2.5 * 3.3 * 6.9 *
W228 1.6 * 2.5 *
W190 * * * * 4.4
W207 * * * 10.2 *
W187 * * * * * 11.9
W204 * * * * 8.4
W206 * * * * 5.9 * 10.2
W211 * * 6.1 7.3 *
W212 * * * 6.2 * 6.6
W218 * * * * * 12.0
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Tab. 5 Time table of 131I treatment and TCR-Mf in treated patients from Belarus 
(continued)
Years
Patient
0 1 2 3 4 5 6 7 8 9 10 11 12
W170 * * * * * * 7.0 11.0
W174 * * * 4.2 2.9
W176 * * * * * 5.9 7.5
W183 * * * 3.4 * 6.0 7.3
W195 * * * * 8.4 * 7.8 *
W197 * * * 8.0 7.4
W141 * * * * * * 4.6 4.6
W092 * * * * * * * 3.8
W117 * * * * 3.1 *
W119 * * * 4.0 4.5
W135 * * * * 7.4
W013 * * * * * * 3.9
W018 * * * * * * * * 4.4 3.6
W058 * * * * * * * * 8.3
W093 * * * * * 4.0
W005 * * * * * 4.3
W014 * * * * * * 5.3
W065 * * * 3.8
W009 * * * * * * * 5.8
W011 * * * * * * * * * * 7.5 5.8
W024 * * * * * * * 6.7
W047 * * * * * * * * 3.5
W053 * * * * * 2.6
W010 * * * * * * * * * 9.5 * 6.6
W035 * * * * * * * * 5.0
W038 * * * * * * * * 2.9
W051 * * * * * * * * 4.7 * 4.3
W054 * * * 2.3
W055 * * * * * 2.8
W180 * * * * * * * 12.2 * 11.8
W036 * * * * * * * * * 2.5
W037 * * * * * * * * * * 3.0
W042 * * * * * * * * * * 4.2
W091 * * * * * * * * * 7.7 * 7.7
Every number represents the value of TCR-Mf times 10-4. Stars (*) represent a 
treatment. Years indicate the number of years passed since the 1st treatment. 
For example ‘ 1.5 * 2.8 * ’ (patient W220) means that Mf at start, or base level, was 
1.510-4. Right after the TCR assay the patient received his 1st treatment. The next 
year he came to the clinic again, and Mf was measured once more, followed by 
second treatment. Initially the level of Mf increases as a consequence of the repeated 
radioiodine therapies but later on Mf goes down due to the elimination of mutants from 
the organism.
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3.2.1.2. A model for the description of the course of TCR-Mf after irradiation
The Mf decay in years following RIT can be described by the three 
parameter single exponential decline function Eq. 4,
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Eq. 5
where 0Mf  is the spontaneous mutant frequency, k - a coefficient showing the 
increase in Mf per 1 mGy radiation dose to red marrow, D – the total dose in mGy 
per treatment, and b – the elimination coefficient of mutants. Its dimension is year-1
and it corresponds to the reciprocal mean residence time of TCR mutants. T is the 
time between measurement of Mf and the treatment in years. The value -0.5 
considers the fact that the maximum of Mf is reached not before a period of about 
half a year. Since most of the patients were treated with radioiodine more than 
once, the level of Mf is described by the sum of i exponential decay functions (Eq. 
5), where i corresponds to the number of treatments. In the present cohort of 
patients the highest number of treatments was ten.
Our goal was to find the values for the coefficients 0Mf , k and b, which fit 
best to the measured mutant frequencies in Tab. 5, where the absorbed dose for 
every treatment (Di), and the time between treatment and the measurement (Ti) 
were known. The values of these coefficients are given in Tab. 6. They were found 
by nonlinear regression analysis of Eq. 5 using the software SigmaStat 1.0. The 
correlation between calculated Mf values and measured values was satisfactory 
(Fig. 2). 
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Tab. 6 Values of the parameters of Eq. 4 and 5
Parameter Value SE CV (%) Dimension
0Mf 2.010-4 3.310-5 15.6
k 6.510-7 10.510-8 12.1 mGy-1
b 2.510-1 3.410-2 15.6 year-1
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Fig. 2 The correlation between the measured and calculated values of TCR-Mf.
None of our patients had the TCR-Mf level deviating considerably from the 
regression curve. If calculated value was significantly lower than measured one,
this could indicate a higher radiosensitivity of the respective patient. 
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3.2.2. Discussion ( Standard TCR Assay )
Some essential parameters of the standard TCR assay are summarised in 
Tab.7. Data were taken or calculated from date in Tab. 6. 
Tab. 7 Parameters of the standard TCR Assay 
Parameter Value*
Spontaneous TCR-Mf 2.010-4
Half life 2.8 years
Doubling Dose 308 mGy
* Data taken or calculated from data in Tab. 6, column 2 
3.2.2.1. Frequency of spontaneous TCR mutants 
The value of Mfo in Tab. 7 partly supports the results of previous 
investigations [28], where the age dependency of TCR-Mf is given by the equation 
Mf ageo     ( . . )1 9 0 02 10 4 . According to this equation, Mfo of a 17 year old 
patient would be 2.2410 4 . The half-life of TCR mutants in peripheral blood was 
2.8 years.
3.2.2.2. Decline of TCR-Mf and its correlation with radiation dose
As a consequence of this slow decay of TCR-Mf, a radiation induced 
increase of Mf will not return to normal before 5 to 15 years (Fig. 3). In patients 
after RIT [4] as well as in gynaecological cancer patients after radiotherapy [29], a 
slightly shorter half-life of mutant T-cells (2 to 3 years) was found. It is worth 
mentioning that T lymphocytes with radiation-induced unstable chromosome 
damage, which die in their first mitosis, could be detected more than ten years after 
exposure [30].
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Fig. 3 Increased TCR-Mf after irradiation and its exponential decay to normal level 
over time. Curves were calculated by Eq. 4 using the values of Tab. 7.
The parameter k gives the increase in TCR-Mf per 1 mGy radiation dose to red 
marrow. Their value are 6.510-7 mGy-1. Akiyama et al. [7] had measured the 
increase in TCR-Mf in radioiodine treated patients as a function of the 131I activity 
administered. They found that Mf increased by 610-5 per 1 GBq administered 
activity. If we assume a body weight of approx 70 kg, this activity would result in a 
red marrow dose of approx. 50 mGy (Eq. 1). The corresponding value of k is 
1210-7 mGy-1. This is approximately 2 times higher than that of our young 
patients. 
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3.2.2.3. TCR–Mf as a biological dosimeter
If there was only one treatment with radioiodine or one X-ray exposure,
TCR-Mf might be used as a biological dosimeter, since the relationship between 
the radiation dose and the maximum of Mf is given by the Eq. 6 as demonstrated in 
Fig. 4. Eq. 6 derives from Eq. 4, if the exponent becomes zero. The radiation 
doses, which doubles TCR-Mf is 310 mGy. Naturally, this calibration curve can 
only be used if the quality of the radiation, the dose-rate, and the dose range are 
comparable with the conditions in radioiodine therapy.
DMfMAX   74 105.61003.2 Eq. 6
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Fig. 4 TCR-Mf as a function of radiation dose to red marrow half a year after 
exposure
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3.3. Assay for latent TCR mutants
A disadvantage of the TCR assay as a biological dosimeter is that it cannot 
be used before about half a year after exposure. This disadvantage might be 
overcome by in vitro incubation of lymphocytes shortly after their irradiation as 
shown by Ishioka et al. [31].
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Fig. 5 Proliferation of irradiated lymphocytes in vitro.
H0 – non-irradiated control, H1 – irradiated with 1 Gy, H2 – irradiated with 2 Gy, H4 – irradiated with 4 Gy
3.3.1. Results (latent TCR mutants)
3.3.1.1. Lymphocyte culture and detection of latent TCR mutants
During this experiment 1) a protocol for the in vitro culture of irradiated 
lymphocytes was optimised (Fig. 5 and Fig. 6), 2) calibration curves of TCR-Mf in 
vitro irradiated lymphocytes were established (Fig. 7), and 3) the standard protocol 
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Fig. 6 TCR-Mf of irradiated lymphocytes during proliferation in culture.
H0 – unirradiated control, H1 – irradiated with 1 Gy, H2 – irradiated with 2 Gy, H4 – irradiated with 4 Gy
for detection of latent TCR mutants was established and tested on patients after 
RIT. At the beginning we wanted to find out the rate of lymphocyte growth and 
profile of TCR-Mf depending on the day of incubation and dose of external 
irradiation. For these purposes blood samples from the same person were 
irradiated in vitro with 1 Gy, 2 Gy and 4 Gy and incubated. The starting 
concentration of cells in the medium was 1*105 cells/ml. Also, the medium was 
diluted throughout the incubation, as soon as the concentration of lymphocytes 
exceeded 106 cells/ml, to prevent the high cells concentration, which would arrest 
cell divisions. Irradiation procedure was described in “Methods” (Section 2.2.2.1).
The cell concentration and TCR-Mf were measured every day and the results 
could be seen in the Fig. 5 and 6. It is worth mentioning that on day 1 the 
concentration of lymphocytes was dropping from 1.2*105 to 0.5*105, and not until 
after 2 days in culture would they start to proliferate. The Mf reaches its maximum 
on day 6 of incubation with clear dependence on the irradiation dose. On day 9 the 
mutant lymphocytes (lacking CD3 receptor) are overgrown by normal lymphocytes
and the Mf goes down. Therefore, TCR assay with incubated lymphocytes was also
performed on day 6 of the incubation, so the maximum of TCR-Mf could be seen.
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Fig. 7 Calibration of the TCR assay after incubation by in vitro irradiation.
The dose rate of irradiation was 0,589 Gy/min. “Not Inc” - stands for the Mf before 
incubation. Irradiation conditions – as described in “Methods”.
In addition the calibration test of irradiating the lymphocytes with doses 
ranging from 0 to 1 Gy was done (Fig. 7). Using these curves the individual 
dosimetry can be done but only if 1) there is linear dependency in vivo between Mf 
and dose up to the 1 Gy 2) if acute in vitro irradiation with 137Cs source 
corresponds to the irradiation received by RIT.
3.3.1.2. Latent TCR mutants in patients treated with radioiodine
Based on the results of previous experiments, cells were incubated for 6 
days. During this time they underwent around 5 divisions and the number of 
measured mutants was found to be at its maximum (see Fig. 6). After in vitro
irradiation with 1 Gy the number of mutants quadrupled in comparison to non-
irradiated sample. Also, the incubation itself had an influence on the base level of 
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mutants. As a rule the Mf after incubation in non-irradiated lymphocytes was lower 
than before (see Tab. 8). Also, occasionally the opposite effect was observed.
For measuring the radiation-induced TCR mutants after RIT 4 different 
lymphocyte probes were measured:
1. Lymphocytes from blood taken before RIT (Mf0)
2. Lymphocytes from blood taken before RIT and incubated for 6 days (Mf0•Inc)
3. Lymphocytes form blood taken before RIT, irradiated with 1 Gy and incubated 
for 6 days  (Mf•1Gy•Inc)
4. Lymphocytes from blood taken 4 days after the begin of RIT and incubated for 
6 days (Mf96•Inc).
Tab. 8 TCR-Mf of lymphocytes after in vitro incubation.
Probes TCR-Mf  x 10-4   (mean  1)
1. RIT (n=8) 2. RIT (n=13)
Dose (mSv) 176  32 439  106
Mf0 2.24  0.71 3.77  1.58
Mf0•Inc 1.54  0.58 2.92  1.44
Mf0•1Gy•Inc 9.10  2.56 9.10  3.12
Mf96•Inc 3.26  0.76 6.51  4.50
The analysis of all parameters was done by Sigma-Stat software. Patients 
treated for the 1st time were analysed separately, because the resulting Mf wasn’t 
influenced by previous RITs. Two types of tests were used: Paired T-test and 
Wilcoxon Signed Rank Test. The paired T-test examines the changes that occur 
before and after a single experimental intervention on the same individual to 
determine whether or not the treatment had a significant effect. Examining the 
changes rather than the values observed before and after the intervention removes 
the differences due to individual responses, producing a more sensitive and
 powerful test. If the distribution of the observed effects was non-parametric, the 
Wilcoxon Test was used. A signed rank test ranks all the observed treatment 
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differences from smallest to largest without regard to sign (based on the absolute 
value), then attaches the sign of each difference to the ranks. The sign ranks are 
summed and compared. This procedure uses the  magnitude of the effects and the 
sign. Paired t-test was preferred when possible (Tab. 9). As a rule, the following 
dependence for TCR-Mf was found: Mf0•Inc < Mf0 < Mf96•Inc << Mf0•1Gy•Inc. 
Tab. 9 Comparison of TCR-Mf values after in vitro incubation
P-Value
1. RIT 2. RIT
SignificanceProbes
t-Test 
(paired)
Wilcoxon t-Test 
(paired)
Wilcoxon
Mf0•Inc  vs  Mf0•1Gy•Inc <0.0001 < 0.0002 Impossible <0,0001 +
Mf0•Inc  vs  Mf96•Inc 0.001 0.0003 0.016 0.0014 +
Mf0        vs  Mf96•Inc 0.007 0.029 0.045 0.026 (+)
Mf0•Inc  vs  Mf0 0.11 0.054 0.16 0.13 -
3.3.2. Discussion (latent TCR mutants)
3.3.2.1. Shortening of the latent period
One of the inconveniences of TCR assay is that it could be used as a 
biological dosimeter only after a latent period of about half year after irradiation. 
This time is needed for mutated lymphocytes to express the mutant phenotype 
resulting in the absence of TCR on their surface. By in vitro incubation of the 
irradiated T-cells we can shorten this latent period to approximately one week.
Mutated lymphocytes are proliferating only if there is still CD3 receptor 
present on their surface. After a few divisions the cells with mutated receptor gene 
stop expressing CD3 receptor (at this moment they could be already detected by 
flow cytometry) and do not divide anymore, whereas normal cells continue to 
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proliferate. If cells are cultured for a longer time, the mutant cells are outnumbered 
by normal proliferating lymphocytes.
The goal of our experiments was to prove the possibility of TCR mutants 
detection in the lymphocytes of RIT patients shortly after exposure. Also, we 
optimized the protocol for in vitro culture of irradiated lymphocytes (Fig. 6) and
established calibration curves for lymphocytes irradiated in vitro (Fig. 7).
3.3.2.2. Latent TCR mutants as a biodosimeter for recent exposure
For TCR assay after in vitro culture and irradiation the doubling dose (dose 
which doubles the rate of spontaneous mutations) can be found using the value 
form Tab. 8 in the Eq. 7. The calculated value is supported by earlier 
measurements of TCR-Mf in patients with latent period of at least 6 months after 
RIT. 
Doubling Dose (RIT)  IncMfIncMf
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The dosimetry for 7 out of 8 patients with 1st RIT, according to Eq. 8,
showed the result of 248  50 mGy. This value is around 1.4 times higher than the 
value obtained by activity measurements (chapter 2.3.2.). In one patient dosimetry 
wasn’t possible, because Mf0 Inc and Mf96 Inc were equal.
The in vitro incubation for early measurements of TCR-Mf is only possible in 
patients with no previous exposure to radiation. Described calculations were not 
possible in patients after the 2nd RIT. The values were either too high or too low to 
be in reasonable range. The reason being that the first RIT, which happened less 
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than half a year before the 2nd therapy, during the incubation gave rise to the extra
mutants.
3.4. MN-Tf-Ret Assay
3.4.1. Results (MN-Tf-Ret Assay)
3.4.1.1. Flow cytometric measurements of micronucleated Tf-Ret
In the present investigation the frequency of micronucleated Tf-Ret was 
measured in patients during the RIT for thyroid cancer. All patients were children or 
young adults, who developed thyroid cancer years after the Chernobyl accident . 
Since Tf-Ret are very rare, they were immunomagnetically isolated from total blood 
before the determination of the f(MN-Tf-Ret) by flow cytometry. Fig. 8 shows the 
dot plots of Tf-Ret fractions before and after 131I administration. Tf-Ret were 
isolated from about 1 ml blood. The purity of the Tf-Ret fraction is remarkable. The 
contamination by mature erythrocytes was below 10% in all preparations. The 
treatment induced a transitory increase in the frequency of MN-Tf-Ret.
3.4.1.2. Short time memory of MN-Tf-Ret Assay
Fig. 9 shows the f(MN-Tf-Ret) in patients before the 1st RIT or more than six 
months after the last treatment respectively. In 41 patients pre-treated for RIT 53 
blood samples were taken at about 7 o'clock in the morning. Before RIT the mean 
f(MN-Tf-Ret) was 1.33  10-3  1.01  10-3 (mean  SD). Three outliers were 
found. Their frequencies were 4.2  10-3, 4.4  10-3 and 5.5  10-3, respectively. 
The f(MN-Tf-Ret) of patients who have already passed some RITs was not higher 
than in patients who have never been treated before. This indicates that the 
organism has a short memory for this radiation-induced mutation. There was no 
significant difference in f(MN-Tf-Ret) between males and females.
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Fig. 8 Flow cytomtric measurements of f(MN-Tf-Ret).
Flow cytometric dot plots of four Tf-Ret samples prepared from a representative 
patient (W010 – Tab. 5) before and after RIT. Hour indications (time points?) in 
each panel correspond to the time of 131I administration. Tf-Ret isolation and flow 
cytometry are described in Methods. Each dot represents one cell. Values for the 
f(MN-Tf-Ret) are given for each time point. Axis X: Thiazole orange fluorescence 
(RNA); Axis Y: HO342 fluorescence (DNA).
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Fig. 9  f(MN-Tf-Ret) in patients before and 6 months after RIT.
f(MN-Tf-Ret) in patients treated for thyroid cancer before their 1st RIT or more than 
6 months after their last one (N=53). In general, previous RITs didn't significantly 
increase the basal level of MN-Tf-Ret in blood. Three exceptions from this rule 
were found with f(MN-Tf-Ret) 4,18*10-3, 4,44*10-3 and 5,49*10-3; they are labelled 
as white triangles.
3.4.1.3. MN-Tf-Ret mutant frequency during RIT
Typical time curves of f(MN-Tf-Ret) are presented in Fig. 10. Therapeutic 
131I activity about 50 MBq in the 1st RIT and about 100 MBq per kg BW in the 
following RITs were administered. The frequency was determined once a day. 
After a latent period of about 2 to 3 days MN frequency rose within one day to a 
maximum. Thereafter, it slowly decreased and reached the level before RIT within
3 to 6 days. The 'short transit' curves belong to two patients with an unusually short 
latent period.
Time curves of the f(MN-Tf-Ret) in patients who were prepared for RIT but 
only received a low diagnostic dose of 131I as they did not need to be treated,
showed no significant increase in MN-Tf-Ret. The dose to red marrow after 131I 
diagnosis is about 20 mSv. This means that neither the radiation dose due to a 
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diagnostic 131I application nor the small dose of the CT scan carried out before RIT 
to detect lung metastases significantly increases the f(MN-Tf-Ret).
Fig. 10 Course of f(MN-Tf-Ret) after therapeutic 131I application.
Dotted curve (1st RIT) and dashed curve (2nd RIT) are from patients, where an 
increase of f(MN-Tf-Ret) was detected earlier than usual.
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Tf-Ret are the youngest reticulocyte cohort in blood. Under steady state 
conditions the number of Tf-Ret that enters blood per minute is equal to the 
number of mature reticulocytes that are transformed to erythrocytes. It was 
investigated, if RIT can impair this equilibrium. During the 1st RIT the frequency of 
reticulocytes remained constant, as should be expected, if RIT does not disturb 
erythropoiesis.
3.4.1.4. Red marrow radiation dose and f(MN-Tf-Ret)
Tab. 10 gives the values of the f(MN-Tf-Ret) as well as of the radiation dose 
to RM in 5 male patients for their first and second RIT, which were performed 9 
months apart. The RM-dose in the second RIT was more than 2 times higher than 
in the first one. The maximal measured f(MN-Tf-Ret) after the second therapy was 
almost twice as that after the first RIT. However, due to the large inter-individual 
variability as well as low number of patients, whose data were available from more 
than one RIT, the difference in response between the two treatments was of low
significance (p=0.03, one-sided sign test).
The relationship between the dose rate of red marrow irradiation and the 
f(MN-Tf-Ret) in peripheral blood for two male patients with normal (left) and 
delayed iodide excretion (right) is shown in Fig. 11 The corresponding residence 
time of 131I in the body (TB ) was 16.9 h and 38.0 h respectively. In the patient with 
delayed excretion the total dose to RM was much higher than in one with normal 
excretion, though the activity given per kg BW was lower.
The upper part of the figure shows that MN-Tf-Ret entered blood, when the 
dose rate of irradiation was already quite low. The figures in the middle give the 
relationship between the total dose to RM and the dose during the last 24 h. Such 
interval was chosen because the cell cycle of an erythroblast lasts about 24 h [32, 
33]. The height of maxima of the 24 h dose curves are quite similar in both patients 
though the value of the total RM dose in one patient was two times higher than in 
the other. The shapes of the 24 h dose curves resemble the time curve of f(MN-Tf-
Ret) in RIT (Top).
Tab. 10 f(MN-Tf-Ret) in five about 19 year old male patients during their 1st and 2nd RIT
Patient 1st RIT 2nd RIT
Dose 
mSv
f(MN-Tf-Ret) (o/oo)
hours after 131I 
Dose 
mSv
f(MN-Tf-Ret) (o/oo)
hours after 131I administration
0 70 96 118 - 7 41 53 65 89 101 113
W229 185 1.3 1.8 6.4 3.9 356 0.6 0.5 0.6 1.4 2.3 10.7 2.1
W230 199 2.9 2.1 11.5 4.5 479 1.0 1.0 1.5 3.3 13.2 8.2 9.1
W231 207 0.8 1.2 5.0 2.7 473 1.9 0.6 0.7 2.0 9.2 20.5 4.9
W232 168 0.9 2.1 7.2 3.3 329 2.0 1.2 1.6 4.2 18.6 16.8 4.4
W233 183 0.8 1.0 9.6 4.3 350 1.6 0.7 0.7 1.5 9.7 8.8 4.1
Mean 188 1.3 1.6 7.9 3.7 397 1.4 0.8 1.0 2.5 10.6 13.0 4.9
SD 15 0.9 0.5 2.6 0.7 73 0.6 0.3 0.5 1.2 6.0 5.4 2.6
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Fig. 11 Relationship between the radiation doses to red marrow and f(MN-Tf-Ret) 
in the blood of a patient with normal (left) and slow (right) radioiodine excretion.The 
131I activity applied was 101 MBq (left) and 82 MBq (right) per kg BW, respectively. 
Top :     f(MN-Tf-Ret) in blood and dose rate to RM.
Middle : Cumulative radiation dose to RM and RM dose within the last 24 h of RIT.
Bottom : Measured and simulated time curve of f(MN-Tf-Ret). 
In simulations the probability for the induction of a micronucleus ( PMN
*
) were 
3.3  10-5 (left) and 3.9  10-5 mSv-1 (right) respectively. The latent interval L was 
63 h (left) and 67 h (right) respectively. Details of the simulation are given in 
Section 3.4.2.4.
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Simulated MN-Tf-Ret time curves are given at the bottom. Simulated curves fit 
quite well to the measured f(MN-Tf-Ret). Similar fits were done in 17 male and 12 
female patients respectively.
Fig. 12 shows the dose dependence of f(MN-Tf-Ret). The values between 
110 and 220 mSv are related to the first RIT whereas all others belong to second 
or later therapies. Within the dose range of 100 to 600 mSv the dose dependence 
is poor. The bold line is the linear regression line for all data. Its parameters as well 
as those of the gender specific regression lines are given in Tab. 11. On average,
the dose dependent increase of MN frequency in men is higher than in women.
Tab. 11 Dose dependence of f(MN-Tf-Ret) in patients after RIT in Fig 12.
Parameters of the regression line   f MN Tf t( Re )  = Y0 + aD
Gender Y0 SE* a  (mSv-1) SE* R2 DoublingRITs 
n  10-3  10-5 Dose (mSv)
Man 24 1.58 0.53 2.27 0. 22 0.69 70
Women 26 1.39 0.53 1.52 0. 21 0.52 91
both 50 1.55 0.40 1.86 0. 16 0.58 83
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Fig. 12 Dose and gender dependence of f(MN-Tf-Ret) in RIT. 
For 51 RIT in 24 women and 22 men the MN frequency in the maximum 3 to 4 
days after 131I administration and the corresponding frequency before treatment are 
given as a function of the total RM dose (Tab. 11). The bold line is the linear 
regression line for the data of all RITs except one. 
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Fig. 13 Timetable of erythropoiesis in man and relative frequency of red 
blood cell (RBC) precursors according to investigations with radiothymidine and 
radioiron [32, 33].
The day, when reticulocytes enter the blood was taken as zero. Most micronuclei 
arise at the last mitosis. They arrive in blood about 70 h later. 
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3.4.2. Discussion (MN-Tf-Ret assay)
3.4.2.1. Transferrin positive reticulocytes in blood as a part of erythron
The knowledge of the timetable of erythropoiesis is a prerequisite for the 
understanding of the course of f(MN-Tf-Ret) in radioiodine treated patients. An 
overview of the size of the different cell fractions of the erythron and the timetable 
of the erythropoiesis is given in Fig. 13. Term erythron refers to the combined 
populations of erythrocytes and their haemoglobin containing precursors in blood 
and bone marrow. The scheme is based on investigations with radiothymidine and 
radioiron, which selectively label all haemoglobin producing and proliferating cells 
[32, 33]. Tf-Ret in blood is a very small fraction of the erythron. They resemble 
Tf-Ret in marrow in cell size and by the presence of cytoplasmic organelles 
(mitochondria and ribosomes) and of transferrin receptors. In blood they belong to 
the so-called immature reticulocyte fraction [34].
3.4.2.2. Role of lifespan of Tf-Ret in peripheral blood
In the present investigation f(MN-Tf-Ret) in blood was measured as an 
indicator  of the f(MN-Tf-Ret) in marrow, where radiation induced MN arise at the 
mitosis of an erythroblast. The red pulp of the spleen plays a key position in the 
maturation of Tf-Ret and elimination of MN-Tf-Ret, since it temporally sequesters 
reticulocytes [35] and removes micronucleated ones. In erythrocytes of patients, 
whose spleen has been removed, not only micronuclei  (Howell-Jolly bodies) but 
also autophagosomes containing mitochondria and ribosomes were found [36]. 
Autosomes are normally absent from mature erythrocytes. 
The relationship between the f(MN-Tf-Ret) in blood and marrow is described by Eq. 
9a and Eq. 9b. It takes into account the fact that under steady state condition the 
number of erythrocytes of a cohort in blood is equal to the product of the respective 
entrance rate  (cells min-1) and the corresponding average lifespan . In Eq. 9b 
values were substituted by the rate constant of transformation of Tf-Ret to mature 
reticulocytes (1) and the rate constant of disappearance MN-Tf-Ret in the spleen 
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(2), where Tf-Ret=1/1 and MN-Tf-Ret=1/(1+2). The ratio of the entrance 
rates from red marrow to blood in Eq. 9a and 9b is approximately equal to the 
f(MN-Tf-Ret) in red marrow. The value f(MN-Tf-Ret)  in blood can only be taken as 
an indicator of f(MN-Tf-Ret) in red marrow, if Tf-Ret  MN-Tf-Ret or 1 >> 2. 
That this condition might be fulfilled is supported by comparing the present data on 
 
  tReTf
tReTfMN
RMBlood tReTf
tReTfMN
tReTf
tReTfMN



 


 


 
Eq. 9a
  
 
  21
1
RMtReTf
tReTfMN










Eq. 9b
baseline f(MN-Tf-Ret) with data on micronucleated polychromatic erythrocytes 
(MN-PCE) in bone marrow smears from control persons [37]. The MN-Tf-Ret 
values are only slightly lower than the MN-PCE values, and this small difference 
may be due to the different scoring methods (flow cytometric vs. microscopic) 
and/or to the lower age of the persons sampled in the present study. 
3.4.2.3. Radiation dose per cycle and f(MN-Tf-Ret) in blood
After 131I administration three typical phases can be discriminated in the 
course of f(MN-Tf-Ret) (Fig. 14A). During the first phase, the latent period L, f(MN-
Tf-Ret) stays at the basal level. It lasts approximately 3 days. The length of the 
latent period corresponds to the transition time required by an orthochromatic 
erythroblast for nucleus extrusion and reticulocyte maturation in marrow (Fig. 13). 
The next phase is characterised by a rapid rise in MN frequency from the basal 
level to the maximum. Its duration is about one day. Within the last phase f(MN-Tf-
Ret) slowly declines to the basal level within several days. The length of this phase 
is the most variable.
This time course of f(MN-Tf-Ret) can be understood if i) MN arise only in the 
last erythroblast mitosis and ii) if f(MN-Tf-Ret) in blood is proportional to the 
radiation dose during the last erythroblast cell cycle, which lasts approximately
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Fig.14   The course of radiation induced MN-Tf-Ret in blood after radioiodine 
administration. 
A. f(MN-Tf-Ret): The course is characterised by a latent period of approx 3 days, a 
rapid rise in frequency between day three and four and a slow decline in the 
following days. Curves were fitted to the data of a patient under the assumption of 
a latent period of 70 h, an erythroblast cell cycle time of 24 h. The value of PMN
was 4.610-5 mSv-1. 
B. Radiation dose: Time dependence of the radiation dose per cell cycle (cycle 
time 24 h) and the total dose to red marrow. 
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24 hours (Fig. 14b). Immediately after the latent period the first radiation induced 
MN-Tf-Ret enter the peripheral blood. In the beginning their frequency is low, since 
the corresponding erythroblasts were irradiated only for a short part of their cell 
cycle. In the following rapid rise of f(MN-Tf-Ret), Tf-Ret that descend from 
erythroblasts exposed for a longer period of the cell cycle enter blood. In the 
maximum of MN-frequency Tf-Ret are for the first time descendants of 
erythroblasts, which were exposed during the whole cycle. They have the highest 
dose per cell cycle of all (Fig. 14b). Later on the dose per cell cycle decreases. 
This explains the slow decline in f(MN-Tf-Ret). 
Occasionally, we found patients after RIT who had a shorter latent period. 
Two examples are given in Fig. 10. In both patients the haematological markers 
(haemoglobin, hematocrit) argue in favour of an iron deficient erythropoiesis and 
anaemia respectively [34]. Anaemia shortens the transit time of reticulocytes [32]. 
Recently some data on the time course of f(MN-Tf-Ret) during a radiotherapy or 
chemotherapy in cancer patients have been published [38]. In most of these 
patients the length of the latent period was shorter than in the present 
investigation, because patients were exposed to acute radiation and most likely 
were anaemic.
3.4.2.4. Model describing the time- and dose-dependence of f(MN-Tf-Ret)
The model is based on the following assumptions, most of which are fulfilled 
in mice for clastogenic agents [39, 40]:
1. MN are induced by radiation during all phases of the cell cycle.
2. MN becomes apparent in the first post-injury mitosis and can be seen in the 
following interphases.
3. The erythropoietic system is in a steady-state and radiation dose not 
disturbed it;
4. Radiosensitivity for MN-induction does not vary throughout the cycle.
5. f(MN-Tf-Ret) increases linearly with the radiation dose. 
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Under these assumptions, the dose- and time-dependency of f(MN-Tf-Ret) in blood 
t hours after radioiodine administration (f(MN-Tf-Ret)D,t) is given by Eq. 10.
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PMN  is the probability that an erythroblast, which arises at mitosis, contains a 
micronucleus, if the progenitor cell was exposed to a dose of 1 mSv during its last 
cell cycle. The relationship between PMN
*
 and PMN  is given by Eq. 11. PMN
*
 is 
equal to PMN , if the lifespan  of MN-Tf-Ret ( tTfMN Re

) and tTf Re  ( tTf Re ) in 
blood are the same. DCT t,  is the dose per cell cycle t hours after RIT begin, L the 
duration of the latent period and T the cell cycle time. The parameters in brackets 
give the contribution of micronuclei arising after the third, second or first 
erythroblast mitosis (Fig. 13), if the cell cycle time in all erythroblast generation is 
24 h and if no cells are lost by apoptosis. The value of the highest measured f(MN-
Tf-Ret) permits a first guess of the value of PMN
*
 (Eq. 12a). For the patient whose 
data are given in Fig. 14a the approximate value of PMN
*
 is 3 0 10 5.    mSv-1
(Eq. 12b), if the cell cycle lasts 24 h. When values for PMN
*
, L and the time curve of 
DCT  are known, the course of f(MN-Tf-Ret) can be calculated.
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The bold curve in Fig. 14a shows the time dependence of 
  t,DtReTfMNf   for this patient, if micronuclei are only induced during the cell 
cycle before the very last erythroblast mitosis. The calculated curve fits to the 
measured values rather well. The dashed curve shows the result of a simulation 
where it was assumed that MN from the last three erythroblast divisions enter the 
blood. Under this assumption the peak of f(MN-Tf-Ret)  is significantly broader than 
actually measured. Similar results were found in all patients, where a sufficient 
number of measurements of f(MN-Tf-Ret) were available to define the time-curve. 
Therefore, we assume that most MN found in Tf-Ret arise at the very last 
erythroblast division. Erythroblasts, in which a MN arises in an earlier mitosis, 
might die. This ineffective erythropoiesis is quite normal in human bone marrow. 
About 10% of the maturing cells die in this way [41]. The calculation was performed 
for an erythroblast cycle time of 24 hours sharp. Our data don't allow to decide if 
CT is a little shorter or longer than 24 h, since in most patients f(MN-Tf-Ret)  was 
only measured once a day. For the same reason it is rather improbable that the 
time and height of the measured MN maximum will correspond to the data of the 
real MN peak. In general, the highest measured value will be significantly lower 
than the real maximum.
Tab. 12 gives the mean values of PMN
*
 found in men and women after RIT. 
The values were calculated by Eq. 12a. There is a significant gender specific 
difference in PMN
*
 (P < 0.005). According to Eq. 9a, differences in the lifespan of 
MN-Tf-Ret and Tf-Ret in blood as well as well gender specific differences in 
radiosensitivity might be the reason. In conclusion, higher doses are needed for 
women to reach the same MN frequency as men. This possibility, however, seems 
to be rather unlikely. Other publications on MN [42-44] support the point that the 
baseline MN frequencies in women are higher than those in men and there is no 
difference in radiosensitivity between genders. However, in this publication the MN 
were measured in lymphocytes and not in reticulocytes. It is possible that the RM 
doses in women were systematically overestimated. 
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Tab. 12  Value of PMN
*
 in patients after RIT
Statistics PMN
*
 10-5  (mSv-1)
Men (N=25) Women (N=25)
Mean  SD 3.8  1.5 2.5  1.4
Median 4.0 2.2
Range 1.3 - 6.6 0.7 - 6.3
3.4.2.5. Adaptation of the model to MN in polychromatic erythrocytes in mice
The counterparts to the reticulocytes in the human blood are the 
polychromatic erythrocytes (PCE) in mice. They represent immature erythrocytes 
with a lifespan in peripheral blood of about 15 h [45]. Contrary to MN-Tf-Ret in 
human, MN-PCE are not cleared by the mouse spleen [46]. As a consequence, the 
lifespan of MN-PCE and PCE in blood are the same. In this case PMN
*
 and PMN
are equal. Many investigations on the MN-induction by ionizing radiation were done 
in mice [45, 47-53]. Fig. 15 gives examples for the MN-PCE frequency in blood of 
mice after acute [45] and chronic [54] radiation respectively. Each point in the left 
part of Fig. 15 represents one irradiated animal. The little scatter of the data 
indicates that in inbred animals the interindividual variation of radiosensitivity is 
small. The time curves were simulated using the kinetic data of mouse 
erythropoiesis and PMN  values, which were hardly higher than the PMN
*
 in human. 
The calculated curves fit remarkably well to the published data. This supports the 
notion that at least in experiments with ionizing radiation the MN-PCE test in mice 
can be used as a model for the MN induction in human erythroblasts.
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Fig. 15 Measured and simulated frequency of MN-PCE in peripheral blood of mice 
as a function of time after irradiation. 
Left.: Acute irradiation with 100 mSv X-rays. MN-PCE were measured by FCM. 
Data were taken from [45]. 
Right: Chronic irradiation with an external 137Cs -irradiator. Dose rate was 
decreased exponentially, with T½ of 64 h. The maximum total dose per cell cycle 
was 116 and 241 mSv respectively. Data were taken from [54]. MN-PCE frequency 
as determined microscopically after staining with acridine orange.  
The following cytokinetic data were used in acute and chronic irradiation, 
respectively: CT of the last erythroblast stage 15 and 14 h, reticulocyte maturation 
time in bone marrow 20 and 14 h, half life of PCE in blood 15 and 10 h. The value 
of PMN  was 610-5 and 710-5 mSv-1.
animals: acute:     male CBA-S mice aged 7-8 weeks
    chronic: female Swiss Webster mice aged 6-7 weeks
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3.4.2.6. Features of the MN-Tf-Ret assay 
As explained above, the increase in f(MN-Tf-Ret) in irradiated people should 
be an indicator of the radiation dose during a distinct time interval, namely the last 
erythroblast cell cycle. As a consequence, this assay is a biological dosimeter, 
which allows to measure the total radiation dose during a time interval that 
corresponds to the average cell cycle time of a polychromatic erythroblast 
(Fig. 13). Measurements in blood are not possible until the latent period of about 3 
days has passed. This feature distinguishes the MN-Tf-Ret assay from most other 
common biological dosimeters such as cytogenetic assays [55], MN in 
lymphocytes [56, 57], or assays that measure somatic mutations in blood cells 
(GPA-, HLA-, HPRT-, or TCR assay) [9]. All these assays are cumulative biological 
dosimeters, which have the potency to determine the total dose accumulated within 
months to years. The MN-Tf-Ret test is not specific for ionizing radiation. In mice 
MN-PCE test was able to register the whole range of genotoxic effects from 
different chemical compounds [58, 59].
In the present investigation the dose dependence of f(MN-Tf-Ret) was weak. 
One reason is that in the present study only a narrow dose range was available for 
study - about 100 to 600 mSv. Also, the relationship between the dose-rate of 
radiation during RIT, and the sampling frequency influences the results. Dose-rate 
decreases exponentially corresponding to the effective half-life of 131I in the patient. 
Under this condition f(MN-Tf-Ret) displays a dose dependent maximum, the height 
of which is proportional to the maximum dose per erythroblast cell cycle. As 
samples were normally taken only once a day, we should have missed the 
maximum in most patients. Shorter sampling intervals are, therefore, needed. Even 
if we knew the time of maximum response, there would be further uncertainty 
regarding the total dose to red marrow, which can be up to twice as high as the 
dose per cell cycle.
After acute irradiation it should be easier to find the precise dose 
dependence. In this situation the dose per cell cycle is constant and equal to the 
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total dose to red marrow.  While the construction of a calibration curve based on in 
vitro exposure is at present not feasible, a study of patients receiving defined acute 
whole-body exposures in the region of 0.1 – 1 Gy would be expected to give a 
more usable dose-response calibration curve. Additionally, a constant, chronic or 
subchronic exposure would in principle give a plateau after an initial latent period 
followed by a period of increase.
There are some features that may make the MN-Tf-Ret assay most useful 
as a biological dosimeter in humans. One is the high sensitivity of the assay, which 
allows the detection of radiation doses as low as 100 mSv. Another advantage 
under some exposure circumstances is the short memory of this endpoint. After 
exposure f(MN-Tf-Ret) returns to normal within a fortnight. This allows the 
retrospective comparison between the spontaneous and the radiation induced 
f(MN-Tf-Ret) on an individual base. The assay also has a well-documented animal 
model counterpart. Finally, the assay can be performed within three days. Thus, 
the method may be of use for monitoring individuals after suspected accidental 
radiation exposure, providing blood samples can be obtained during a few days 
after the presumed exposure.
3.5. Biological dosimetry in radioiodine treated patients
Table 13 gives a short synopsis of biodosimetry in patients after RIT. Beside 
the assays used in the present investigation other methods were applied. They
include:
1. MN in lymphocytes assay [60-67].
For this assay lymphocytes are cultured for 44 hours. Afterwards 
cytochalasin B is added. It blocks cytokinesis and makes possible the detection of 
lymphocytes dividing in culture. Cells that have undergone the first mitosis are 
recognised as binucleated, and they are screened for presence of micronuclei.
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Tab. 13 Biological dosimetry in radioiodine treated patients
Assay Doubling Dose Time interval Biodosimeter Time
mGy of applicability characteristic consume
MN-Tf-Ret *
Assay
70 - 100 3 - 4 d Recent 2 d
Standard *
TCR assay
200 - 300 0,5 – 5 y Cumulative 6 h
TCR assay *
after cell culture
200 - 300 1 d – 3 mo ? Cumulative 1 w
GPA  assay * 500 - 600 0,5 y -∞ Cumulative 3 d
MN-Assay in 
Lymphocytes **
100 1 d –6 mo Cumulative 3 d
Chromosome ** 
Aberrations
200 1 d –1 y Cumulative 3 d
* Detection of altered cells by flow cytometry ** microscopic detection
2. Chromosome aberrations assays [68-75].
Fluorescence in Situ Hybridisation (FISH). Stained chromosome slides are 
analysed under the fluorescence microscope by visual scoring of translocations, 
insertions, deletions and breaks. 
Sister chromatid exchange (SCE) method. The test is based on the 
exchange of 5-bromodeoxyuridine with thymine nucleotide in the chromosomes of 
newly multiplied lymphocytes. The chromosomal uptake site of the 5-
bromodeoxyuridene does not permit staining, while thymine does.
3. Glycophorin A Assay [7, 51, 76, 77].
The glycophorin A (GPA) assay concurrently detects and quantifies two 
types of erythrocytes with variant phenotypes at the autosomal locus responsible 
for the polymorphic MN blood group. It uses a pair of allele-specific monoclonal 
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antibodies and flow cytometry to analyse a standard population of 5 million cells 
efficiently. The two phenotypes detected are simple allele loss and allele loss 
followed by reduplication of the remaining allele; both are consistent with the 
mechanisms underlying "loss of heterozygosity" at tumour suppressor genes.
The data in the table 13 demonstrate that TCR assay and the MN-Tf-Ret 
assays are potent methods for biological dosimetry. Their use could be 
recommended for monitoring of radiation therapy and radiation accidents.
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4. Summary
In radiation accidents biological methods are used in dosimetry, if the 
radiation dose could not be measured by physical methods. The knowledge of 
individual dose is a prerequisite for planning a medical treatment and for health risk 
evaluations.
In the present work two biodosimetrical assays were calibrated in young 
patients who were treated with radioiodine for thyroid cancer. Patients were from 
Belarus. They suffered from radiation induced thyroid cancer as a consequence of 
the Chernobyl reactor accident.
In radioiodine therapy (RIT) bone marrow and lymphatic organs are 
exposed to ionizing radiation at doses of 0.1 to 0.75 Sv within about 2 days. Since 
several RIT have to be applied with interval between each of them from 6 months 
up to approximately 1 year, total dose can be up to 2 Sv within 2 to 3 years. The 
dose for thyroid tissue is approximately 1000 times higher.
The dose-response relationship was measured by the T-cell receptor test 
(TCR test) in T4 lymphocytes with and without in vitro incubation or by the 
micronucleus assay in transferrin receptor positive reticulocytes (MN-Tf-Ret test). 
In all these assays, the frequency of radiation-induced mutants of blood cells is 
measured using flow cytometry. The TCR test is a cumulative biodosimeter, which 
measures the total radiation dose within the last 5 to 10 years, whereas the result 
of the MN-Tf-Ret test reflects the radiation dose of approximately 24 hours interval. 
It takes 8 hours and 3 days to perform TCR and MN-Tf-Ret tests respectively.
Calibration curves based on radioiodine treated patients can be used for 
dose estimation in humans, if the radiation conditions correspond to those in RIT. 
This limits their applicability to low dose-rate β- and γ-irradiation and to doses per 
session not higher than about 0.5 Sv. If higher doses or dose-rates as well as the 
other types of ionizing radiation are involved, calibration curves in animals are 
indispensable. In the case MN-Tf-Ret test mouse models are established and may 
be used.
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The TCR assay was performed in 72 thyroid cancer patients aged between 
14 and 25. T-cell mutant frequency (Mf) reaches its maximum only after half a year 
following the RIT. Then it declines exponentially. This decline could be described 
by the 3 parameter single exponential decay function.
Based on this equation, the radiation dose could be calculated when the Mf 
and the time interval since exposure are known. Furthermore, the experimentally 
measured Mf value, which significantly exceeds the corresponding calculated Mf 
value would indicate an individual with higher radiosensitivity. However, among our 
patients there were none.
The reticulocytes micronuclei test (MN-Tf-Ret) was performed in 46
radioiodine treated patients [78]. When measuring the MN frequency (f(MN-Tf-
Ret)) the measured cell fraction should be limited only to the youngest cohort of 
reticulocytes, because all the micronucleated erythrocytes are quickly removed 
from the peripheral blood by spleen. Thus, the MN test was performed only in 
CD71 positive (having transferring receptor) reticulocytes. These reticulocytes just 
entered the peripheral blood flow from red marrow.
The MN frequency was measured before the therapy and then every day 
after the irradiation until day 7. MN frequency curve has typical shape with latent 
period for days 0 to 3. Then there is a sharp increase in MN frequency which lasts 
for 24 hours and could start between days 3 and 4. In the following days the MN 
frequency is dropping to its base level that equals the one before the treatment. 
The decay of MN frequency is depending on the half-life of radioiodine in the 
patient organism. If the half-life is low, then the increased f(MN-Tf-Ret) lasts 
shorter and vice versa.
It was shown that the MN frequency curve could be described by the model 
where all the micronuclei arise only through the last mitosis of erythroblasts in the 
red marrow and the MN frequency is proportional to the radiation dose in the last 
cell cycle.  The shape of this curve depends on the cell kinetics of erythropoiesis 
on one side and the exponential decay of radioiodine activity on the other. To the 
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best of our knowledge, the MN-Tf-Ret test was applied in the present study for the 
first time in biological dosimetry.
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6. Abbreviations
BW - body weight
f(MN-Tf-Ret) - frequency of micronucleated transferrin positive reticulocytes
FBS - fetal bovine serum
FCS - fetal calf serum
GPA - glycophorin A
HPRT - hypoxanthine-guanine phosribosyl transferase
ICRP - International commission on Radiological Protection
Mf - mutant frequency
MIRD - Medical Internal Radiation Dose
MN - micronuclei
MN-PCE - micronucleated polychromatic erythrocytes
MN-Tf-Ret – micronucleated transferrin-positive reticulocytes
MPC – magnetic particle concentrator
PCE - polychromatic erythrocytes
RI - radioiodine
RIT – radioiodine treatment
RM – red marrow
RT – residence time
TB – total body
TCR – T-cell receptor
TCR-Mf – T-cell receptor mutants frequency
Tf-Ret – transferrin-positive reticulocytes
TSH - thyroid-stimulating hormone
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